Michael Henry, Ph.D.
        Associate Professor
        Associate Professor of Pathology

Office: Lab: Phone: Lab: FAX: Email:

6-510 Bowen Science Building 6-509 Bowen Science Building (319) 335-7886 (319) 335-7887 (319) 335-7330 michael-henry@uiowa.edu

Research Interests

The long term research goals of my laboratory are to understand the molecular and cellular basis of prostate cancer progression and metastasis in order to develop new methods for the diagnosis and treatment of this disease. Current efforts are focused on the role of a cell-matrix receptor dystroglycan and epithelial-mesenchymal transition in this process. Emerging interests include the development of mouse model to study how physiological and environmental components interact with PI3K-Akt signaling pathway known to be involved in prostate cancer progression.

Selected Publications

1. Drake, J.M., Gabriel, C L. and Henry, M.D. Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. Clin. Exp. Metastasis, 22:674-684, 2005.

2. Svensson, R.U., Barnes, M.J. Rokhlin, O., Cohen, M.B. and Henry, M.D. Chemotherapeutic Agents Upregulate the CMV Promoter via p38 MAPK: Implications for Bioluminescence Imaging of Tumor Response to Therapy. Cancer Research, 67:10445-10454 , 2007.

3. Svensson, R.U., Shey, M.R., Ballas, Z.K., Dorkin, J.R., Goldberg, M., Akinc, A., Langer, R., Anderson, D.G., Bumcrot, D. and Henry, M.D. Assessing siRNA pharmacodynamics in a luciferase-expressing mouse. Molecular Therapy,16:1995-2001, 2008.

4. Weydert, C.J., Esser, A.K., Mejia, R.A., Drake, J.M., Barnes, J.M., Henry, M.D. Endothelin-1 inhibits prostate cancer growth in vivo through vasoconstriction of tumor-feeding arterioles. Cancer Biol. and Ther., 8:62-71, 2009.

5. Drake, J.M., Strohbehn, G.S., Bair, T.B., Moreland, J.G., Henry, M.D. ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells. Mol. Biol. Cell, 20:2207-2217, 2009.